Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD6738 + Paclitaxel in Refractory Cancer
NCT02630199Phase 1Completed
- Sponsor
- Samsung Medical Center
- Start
- Dec 2015
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ceralasertib in solid tumor, sponsored by Samsung Medical Center. Primary endpoints: Number of participants With Abnormal Laboratory Values and/or Adverse Events and Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0 to determine maximal tolerate dose up to 6 months. Started Dec 2015; status: completed.
02
Drugs
ceralasertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02630199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02630199.